Entering text into the input field will update the search result below

Moderna, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 06, 2021 1:55 PM ETModerna, Inc. (MRNA)9 Comments
SA Transcripts profile picture
SA Transcripts

The following slide deck was published by Moderna, Inc. in conjunction with their 2021 Q1 earnings call.

DNA                       mRNA                      Protein

This article was written by

SA Transcripts profile picture
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Recommended For You

Comments (9)

Impressive results. Clearly, Moderna believes there will be significant sales in 2022. 89% profit margin (I assume excluding SG&A) is phenomenal. CMV vaccine in P3. PCV, OX40L, VEGF in P2. Preparing for Phase 2 trialfor Zika; expected to begin in 2021. Phase 1 study of mRNA-1010 (Flu) expected to begin in 2021.
The only negative I saw in the presentation was the substantial increase in the number of diluted shares in the quarter (77MM). Presumably much of this is due to the exercise of option grants.
Craig69 profile picture
We just have to hope that slippery Joe and his cohorts stay out of the way:-)
Interesting upcoming product lineup. Flu combo in 2023. A suite (CVM, PCV, EBV, Zika, VEGF, OX-402) planned in 5-10 yrs for a 10x impact (rev?). 2022 is for C19 variants and booster, much in APA already. Rev will be higher than 2021. I feel the story clear & buz plan aggressive but realistic. With this good visibility, rev and earning models can be updated. We will see updates soon from Street. When next two meds (likely CMV and flue combo) approved with others inline, the 5x MC is realistic in 2-3 yrs. I like the ER call and slides.
Moderna is doing everything right!
Chihawk Research profile picture
Basically trading at 6 times this year's earnings and about 3.3x revenue with a scaled product and a year of Advanced Purchase Agreements. Right.
Krypto profile picture
Very impressive!
jara-mill profile picture
@Krypto - MOST impressive (as Darth Vader would say)
@Krypto indeed. Surprised to see this much APA for 2022 already. I like their “just do it” attitude, unlike NVAX just words.
jara-mill profile picture
@ScienceMatters - Moderna = NIKE; Novavax = Reebox
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About MRNA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on MRNA

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.